Blood Journals Studio

Scientific Workshop on Bruton Tyrosine Kinase Pathway Biology in Chronic Lymphocytic Leukemia: Resistance, Intolerance and Next-Generation Translational Research

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Martin Cabero-Becerra, MD, PhD
Hospital Universitario Mancha Centro
Alcazar de San Juan, Spain
[email protected]

Paolo Ghia, MD, PhD
Universita Vita-Salute San Raffaele
Milan, Italy
[email protected]

Bruton’s Tyrosine Kinase (BTK) inhibitors have transformed Chronic Lymphocytic Leukemia (CLL) treatment, but their long-term use has created unresolved biological questions that are not adequately addressed by standard clinical sessions. This workshop will examine why resistance emerges under BTK pathway pressure, why intolerance develops in selected patients, and how these processes should be studied using molecular diagnostics, immune profiling, inflammatory biomarkers, measurable residual disease (MRD) kinetics and serial biological sampling.

Target Audience: Laboratory-based and translational investigators working in CLL, B-cell receptor signaling, molecular diagnostics, immunogenetics, immune profiling, MRD assessment, clonal evolution, therapy resistance and treatment-related toxicity biology.

Objectives:

• Define a focused translational research agenda for BTK pathway biology in CLL.
• Discuss a shared framework for biomarker-driven translational cohorts studying BTK inhibitor resistance, intolerance and next-generation BTK pathway targeting in CLL.

Workshop Program: The full workshop program with speakers will be available at a later date.

If you would like to request a speaking slot at this workshop, please contact the workshop co-chairs directly.

Scientific Workshop on Emerging Technologies and Innovations in Diagnostic Hematology

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Christopher Park, MD, PhD
NYU Grossman School of Medicine
New York, NY
[email protected]

Gerlinde Wernig, MD
Stanford University
Stanford, CA
[email protected]

Sanjay Patel, MD, MSc, MPH
Weill-Cornell Medicine
New York, NY
[email protected]

Diagnostic hematology is being transformed by molecular diagnostics, spatial biology, single-cell and multi-omic profiling, next-generation and full-spectrum flow cytometry, digital pathology, and artificial intelligence/machine learning. These advances are reshaping disease classification, biomarker discovery, measurable residual disease assessment, and clinical trial design, while creating new opportunities to improve the biologic understanding of hematologic disorders. This workshop will focus on the scientific foundations, analytic frameworks, and emerging research applications of these technologies.

Target Audience: Investigators interested in advancing biologically grounded diagnostic methods for hematologic diseases to improve disease classification, diagnostic accuracy, and prediction of clinical outcomes. The program will appeal to hematologists, hematopathologists, laboratory medicine specialists, basic and translational researchers, and trainees.

Objectives:

• Advance the integration of innovative technologies and analytical methods into the clinical hematology laboratory.
• To bring together complementary perspectives across hematopathology, hematology, and laboratory medicine.

Workshop Program: The full workshop program with speakers will be available at a later date.

If you would like to request a speaking slot at this workshop, please contact the workshop co-chairs directly.

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Lucy Fox, MBBS, BCom/BSc, FRACP, FRCPA, DMedSc
Peter MacCallum Cancer Centre
Melbourne, Australia
[email protected]

Marcin Wlodarski, MD, PhD
St. Jude Children’s Research Hospital
Memphis, TN
[email protected]

Recognition of germline predisposition to hematopoietic malignancies (HMs) and bone marrow failure (BMF) has become an integral part of hematology/oncology practice. Predisposing germline variants are now recognized to occur far more frequently than previously assumed. Although identified genes have revealed novel molecular pathways, substantial gaps exist in the understanding of the precise mechanisms underlying these disorders, the optimal strategies for molecular surveillance of affected individuals, and the development of precision therapies.

This workshop will feature four strategic sessions covering: (i) diseases and mechanisms; (ii) precision genomic medicines in BMF; (iii) novel insights in molecular surveillance of at-risk individuals; and (iv) new scientific discoveries in the field.

Target Audience: International investigators who are actively studying HMs and BMF, trainees, and clinicians.

Objectives:

• Discuss on-going research efforts in germline predisposition disorders.
• Discuss the novel biology of predisposition syndromes.
• Highlight precision genomic medicines and clinical translation.
• Discuss novel approaches to molecular surveillance of at-risk individuals.

Workshop Program: The full workshop program with speakers will be available at a later date.

If you would like to request a speaking slot at this workshop, please submit your abstract by August 10, 2026.

Download Form

Scientific Workshop on Interplay Between Coagulation and Malignancy

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Lisa Baumann Kreuziger, MD, MS
Versiti, Blood Research Institute
Milwaukee, WI
[email protected]

Jeffrey Zwicker, MD
Memorial Sloan Kettering Cancer Center
New York, NY
[email protected]

Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer, who also represent the highest-risk group for developing VTE. Despite considerable epidemiologic research, the mechanisms underlying thrombosis in cancer remain poorly understood. This workshop will feature short research presentations with equal emphasis on discussion — fostering meaningful exchange among basic and translational researchers working at the intersection of cancer and thrombosis.

Target Audience: Translational and basic researchers as well as clinicians interested in the mechanisms of thrombosis in cancer patients and how thrombosis may influence the progression of cancer. Clinical researchers may benefit from the workshop to understand the mechanisms of disease and identify potential collaborations. Early career and senior investigators will be encouraged to facilitate mentoring opportunities.

Objectives:

• Provide a unique forum to discuss the latest scientific developments in cancer and thrombosis.
• Enhance current collaborations, develop new collaborations, and provide opportunities for interaction between junior and established investigators in cancer and thrombosis.

Workshop Program: The full workshop program with speakers will be available at a later date.

If you would like to request a speaking slot at this workshop, please contact the workshop co-chairs directly.

Scientific Workshop on Mechanism‑Driven Biomarkers in Sickle Cell Disease

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Karina Yazdanbakhsh, PhD
New York Blood Center
New York, NY
[email protected]

Thomas Coates, MD
Children’s Hospital Los Angeles
Los Angeles, CA
[email protected]

Sickle Cell Disease (SCD) is a complex monogenic disorder characterized by vast clinical heterogeneity. The diversity of clinical phenotypes is likely due to underlying heterogeneity in the underlying pathophysiological cascades downstream of sickle Hb polymerization, such as chronic hemolysis, vaso-occlusion, and systemic inflammation. Traditional hematological markers often fail to capture the full spectrum of individual disease trajectories. Mechanistic biomarkers derived from the core biology of SCD are essential for diagnostic, prognostic, and therapeutic insights. Embedded in disease pathogenesis, they reflect precise, target-driven interactions rather than just correlations. This workshop will highlight insights into future research directions for this mechanistically complex disease.

Target Audience: Basic and translational scientists, clinicians, pharmaceutical companies and government (NIH, FDA) agency representatives.

Objectives:

• Highlight recent technological-and mechanistic advances that elucidate novel SCD pathophysiologies and inform biomarker discovery and development.
• Describe mechanisms underlying SCD-specific changes in blood and endothelial cells.
• Evaluate how complement dysregulation and thromboinflammation predict disease- and organ-specific severity.
• Examine genetic modifiers for stratified clinical interventions and multi-platform omic studies for profiling disease- and organ-specific severity.

Workshop Program: The full workshop program with speakers will be available at a later date.

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:
Sarah Skuli, MD, PhD
University of Cincinnati
Cincinnati, OH
[email protected]

Marina Konopleva, MD, PhD
Albert Einstein College of Medicine
New York, NY
[email protected]

Jean-Emmanuel Sarry, PhD
Cancer Research Center of Toulouse
Toulouse, France
[email protected]

Mitochondrial biology and cellular metabolism are central determinants of malignant cell survival, therapeutic response, and disease progression across hematologic malignancies. This workshop will deliver concrete, actionable takeaways beyond knowledge exchange, including practical frameworks to interrogate metabolic dependencies, guidance on integrating metabolic assays into preclinical/clinical studies, and exposure to emerging tools such as metabolomics, mitochondrial functional analyses, and computational approaches for large-scale data integration. Attendees will gain insights directly applicable to their own research programs.

Target Audience: Basic scientists, translational researchers, and clinician-investigators (spanning all career stages) studying metabolism across leukemias, lymphomas, and myeloma.

Objectives:

• Highlight fundamental discoveries in metabolism that inform clinically relevant challenges in blood cancers.
• Identify metabolic and mitochondrial vulnerabilities, including in the tumor microenvironment, that can be therapeutically targeted in blood cancers.

Workshop Program: The full workshop program with speakers will be available at a later date.

If you would like to request a speaking slot at this workshop, please contact the workshop co-chairs directly.

Scientific Workshop on Myeloid Development

Friday, December 11, 2026, 2:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Patricia Ernst, PhD
University of Colorado Denver
Denver, Co
[email protected]

Ulrich Steidl, MD, PhD
Albert Einstein College of Medicine
New York, NY
[email protected]

The workshop will cover the basic science of myeloid development or pathophysiology, and while individual talks can have more translational components, there will be no presentations primarily focused on clinical findings. Presentations cover molecular and cellular biology, systems biology, biochemistry, bioinformatics, animal models, and study of human cells and patients to address key topics in myeloid biology. Talks feature emerging data from cutting-edge research groups, expected to have broad and lasting impact.

This workshop will only be available to people who attend the Annual Meeting in person and will not be livestreamed to a virtual audience. A recording of the workshop will be available at the conclusion of the workshop on the virtual meeting platform until 11:59pm PT on January 1st, 2027.

Target Audience: Laboratory-based/translational investigators, including trainees, with many interests surrounding normal and pathological myeloid/stem cell biology.

Objectives:

• To provide a venue for early career and established investigators to present their newest cutting-edge science to the myeloid community.
• Offer an opportunity for informal discussion and feature late-breaking science. Provide trainees a chance to hear new scientific concepts and to meet leaders in our field.
• Highlight emerging new concepts in myeloid biology that will or have the potential to broadly impact hematology and oncology.

Workshop Program: The full workshop program with speakers will be available at a later date.

If you would like to request a speaking slot at this workshop, please contact the workshop co-chairs and the appropriate section leaders (see below) directly:

• Stem Cells: Eric Pietras, PhD ([email protected])
• Transcription and Epigenetics: Kathrin Bernt, MD ([email protected])
• Signaling and Development: Kira Gritsman, MD, PhD ([email protected])
• Myeloid Malignancies: Zuzana Tothova, MD, PhD ([email protected])

Scientific Workshop on New Frontiers in T-Cell Acute Lymphoblastic Leukemia Biology: Metabolism, Genomics, and Microenvironment

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Ksenia Matlawska-Wasowska, PhD
University of Alabama at Birmingham
Birmingham, AL
[email protected]

Daniel Herranz, PharmD, PhD
Rutgers Cancer Institute
New Brunswick, NJ
[email protected]

This workshop will bring together leading investigators studying transcriptional and epigenetic regulation, metabolic reprogramming, leukemia-microenvironment interactions, inflammatory signaling, and emerging experimental models in T-Cell Acute Lymphoblastic Leukemia (T-ALL). Particular emphasis will be placed on integrating leukemia cell-intrinsic programs with non-cell-autonomous mechanisms mediated by stromal, immune, and tissue-specific microenvironments. The workshop will highlight cutting-edge technologies, including single-cell and spatial transcriptomics, multi-omics profiling, advanced in vivo modeling, and functional genomic approaches that are reshaping our understanding of T-ALL biology and therapeutic vulnerabilities.

Target Audience: Laboratory-based investigators, translational researchers, physician-scientists, clinicians, and early-career investigators interested in T-ALL biology, transcriptional and epigenetic regulation, metabolic reprogramming, leukemia-microenvironment interactions, central nervous system leukemia, and emerging therapeutic vulnerabilities.

Objectives:

• To highlight emerging biological mechanisms regulating T-ALL progression, dissemination, and therapeutic adaptation. Integrate genomic, epigenetic, metabolic, inflammatory, and microenvironmental perspectives in T-ALL biology.
• Discuss novel technologies and experimental models, including single-cell, spatial, and multi-omics approaches, for studying leukemia progression and therapeutic vulnerabilities.
• Foster engagement, mentorship, and networking opportunities for early-career investigators within the international T-ALL research community.

Workshop Program: The full workshop program with speakers will be available at a later date.

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Panagiotis Ntziachristos, PhD
Ghent University
Ghent, Belgium
[email protected]

Daniel Starczynowski, PhD
Cincinnati Children’s Hospital
Cincinnati, OH
[email protected]

Christina Glytsou, PhD
Rutgers University
New Brunswick, NJ
[email protected]

Aristotelis Tsirigos, PhD
NYU Grossman School of Medicine
New York, NY
[email protected]

Resistance to therapy remains the principal obstacle to durable response in hematologic malignancies. Despite the accelerating pace of targeted therapies, the molecular mechanisms underlying both preexisting and acquired resistance remain incompletely defined, and clinically deployable strategies to anticipate or reverse resistance continue to lag behind.

This workshop will address this challenge by integrating three converging mechanistic axes (chromatin biology and clonal evolution, RNA-level regulation, and protein-level vulnerabilities at the microenvironment-inflammation interface), with modern computational analyses serving as an explicit methodological thread across all three sessions and the bone-marrow microenvironment as a unifying biological context for the resistance phenomenology.

Target Audience: Researchers, clinicians, and other health professionals interested in the underlying causes of therapy resistance in blood disorders. Both early-career and experienced investigators are encouraged to participate to foster mentoring, networking, and collaboration.

Objectives:

• Help scientists and clinicians understand the molecular mechanisms of resistance to therapy in blood malignancies.
• Integrate the diverse genetic and non-genetic mechanisms of resistance (chromatin biology and clonal evolution, RNA-level regulation, and protein-level vulnerabilities at the microenvironment-inflammation interface) into a coherent translational framework.
• Showcase emerging technologies reshaping the resistance landscape, including molecular glues, targeted protein degraders, machine-learning-driven single-cell analyses, spatial transcriptomics, and intravital microscopy. Provide a structured forum for panel-driven discussion and promote collaboration, technology exchange, and networking to help early-career investigators.

Workshop Program: The full workshop program with speakers will be available at a later date.

If you would like to request a speaking slot at this workshop, please contact the workshop co-chairs directly.

Scientific Workshop on TP53: A Moving Target

Friday, December 11, 2026, 3:00pm – 6:00pm CT
New Orleans, Louisiana

Co-Chairs:

Jonathan M. Gerber, MD
University of Massachusetts Chan Medical School
Worcester, MA
[email protected]

Ann-Kathrin Eisfeld, MD
Ohio State University Medical Center
Columbus, OH
[email protected]

Mutations in TP53 confer very poor prognoses in myeloid neoplasms, with limited treatment options. Understanding TP53 mutations across the spectrum of myeloid neoplasms represents a desperate unmet need in hematology, reflected by its recognition as a unique disease entity by classification (e.g., The World Health Organization and International Consensus Classification) and prognostication guidelines. Many fundamental questions remain unresolved at the levels of clonal initiation, allelic status, cooperating lesions, immune interaction, vulnerabilities, and the microenvironment. Furthermore, little is currently known about the impact of low-frequency and cryptic variants on disease biology and resistance. 

This workshop is designed to address controversies and unknowns in how TP53 alterations are defined, measured, interpreted, and targeted. Presenters will discuss TP53 biology, interactions, detection, and targeting using state-of-the-art single-cell, multi-omic, and functional approaches to catalyze new experimental approaches and collaborations.  

Target Audience: Basic and translational clonal hematopoiesis researchers, molecular pathologists and genomic laboratory scientists, tumor immunology investigators, clinical, basic, and translational investigators in myeloid malignancies, clinicians aiming to better understand the impact of TP53 in clonal hematopoiesis, including myelodysplastic syndrome and acute myeloid leukemia, trainees, including hematology/oncology fellows

Objectives:

• Clarify how TP53 mutations arise and contribute to evolution from clonal hematopoiesis to overt myeloid malignancy.
• Define and standardize TP53-related biological features, including allelic states, co-mutations, and microenvironmental interactions, as well as possible strategies to detect and target TP53 mutant myeloid diseases, using multi-omic and functional approaches.
• Identify key research priorities, shared resources, and experimental strategies to accelerate basic and translational TP53-focused science in hematology.

Workshop Program: The full workshop program with speakers will be available at a later date.

The ASH Blood Journals Studio, centrally located in the poster hall, is the place to learn about the Society's Blood journals portfolio, meet the editors, and network with peers and experts in your field. It is a perfect opportunity to connect with editors in a more informal setting, find educational opportunities, and learn about the Society's portfolio of journals. The Blood Journals studio is only offered in person.

Additional information will be available in Fall 2026.